B·R·A·H·M·S™ sFlt-1 KRYPTOR™

B·R·A·H·M·S provides a complete portfolio of biomarkers for the management of pre-eclampsia throughout pregnancy. B·R·A·H·M·S sFlt-1 KRYPTOR together with B·R·A·H·M·S PlGF plus KRYPTOR is indicated as an aid for early prediction, diagnosis and prognosis of pre-eclampsia from week 20 and an identification of women at risk of developing term pre-eclampsia at week 36. Get confidence in your results with the high precision of B·R·A·H·M·S sFlt-1 KRYPTOR and get results in less than 30 minutes.

• Incubation time of only 9 minutes for a short turnaround time
• Allows measurement in serum and plasma (EDTA)
• Large capacity with 75 tests
• Kit stable up to 29 days after opening onboard the instrument
• Easy workflow with only 2 calibrators and one calibration every 2 weeks
• Fits your throughput need with B·R·A·H·M·S KRYPTOR compact PLUS or B·R·A·H·M·S KRYPTOR GOLD
• Easy to use with sFlt-1/PlGF ratio calculated by the instrument

• Intended Use for US Only: The B·R·A·H·M·S™ sFlt-1/ PlGF KRYPTOR™ Test System is comprised of the B·R·A·H·M·S PlGF plus KRYPTOR assay and the B·R·A·H·M·S sFlt-1 KRYPTOR assay. The B·R·A·H·M·S PlGF plus KRYPTOR is to be used in conjunction with the B·R·A·H·M·S sFlt-1 KRYPTOR along with other laboratory tests and clinical assessments to aid in the risk assessment of pregnant women (singleton pregnancies between gestational age 23+0 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension) for progression to preeclampsia with severe features (as defined by American College of Obstetricians and Gynecologists guidelines) within 2 weeks of presentation.